Despite efforts to develop increasingly targeted and personalized cancer therapeutics, dosing of drugs in cancer chemotherapy is limited by systemic toxic side effects. We have designed, built, and deployed porous absorbers for capturing chemotherapy drugs from the bloodstream after these drugs have had their effect on a tumor, but before they are released into the body where they can cause hazardous side effects. The support structure of the absorbers was built using 3D printing technology. This structure was coated with a nanostructured block copolymer with outer blocks that anchor the polymer chains to the 3D printed support structure and a middle block that has an affinity for the drug. The middle block is polystyrenesulfonate which binds to doxorubicin, a widely used and effective chemotherapy drug with significant toxic side effects. The absorbers are designed for deployment during chemotherapy using minimally invasive image-guided endovascular surgical procedures. We show that the introduction of the absorbers into the blood of swine models enables the capture of 64 ± 6% of the administered drug (doxorubicin) without any immediate adverse effects. Problems related to blood clots, vein wall dissection, and other biocompatibility issues were not observed. This development represents a significant step forward in minimizing toxic side effects of chemotherapy.

Our data suggest that SB might be superior to LA for DBS surgery with respect to BP control and hemodynamics. The need for analgesics does not differ substantially between both anesthetic treatment options.

Bosentan has lately been described as a successful therapeutic agent for portopulmonary hypertension consecutive to child A cirrhosis. This is the first report of the effect of this substance with advanced liver cirrhosis (child C) and renal insufficiency. Low doses of bosentan (initially twice 31.25 mg/day and then 62.5 mg/day) increased cardiac output and allowed correction of renal insufficiency; it allowed one to stop the requirement of oxygen and not only improved the 6-min walking test by more than 400 m, but also decreased the severity of the liver cirrhosis to child B stadium. This suggests that patients, who would be excluded from a liver transplantation program because of their portopulmonary hypertension, could profit from a careful therapy with bosentan.

No abstract

Die Problematik des AC-Gelenk-Schadens, ob frisch oder chronisch, liegt in ▂ der schmerzhaften Bewegungseinschränkung, ▂ der fehlenden Belastbarkeit der Schulter und ▂ bei schlanken Patienten in der Deformität des Schulterprofils. Ursachen Die häufigste Ursache der Schultereckgelenkverletzung ist der Sport-und Freizeitunfall mit einem direkten Anpralltrauma auf die Schulterspitze bei adduziertem Arm.Seltener sind ein direktes Trauma auf den ausgestreckten Arm oder Sturz auf den Ellenbogen. In der Häufigkeit folgen Verkehrsunfälle-darunter v. a. Zweiradunfälle-und Arbeitsunfälle. Diagnose Eine exakt erhobene Anamnese ist richtungsweisend, die vermutete Diagnose lässt sich bereits durch eine klinische Untersuchung erhärten. Inspektorisch zeigt sich eine schmerzhafte Schonhaltung des Arms. Bei der frischen Verletzung wird der Arm meist am Körper gehalten und von der Hand der Gegenseite im Ellenbogenbereich unterstützt. So wird das schmerzhafte Eigengewicht des Arms neutralisiert. Vielfach zeigen sich Abschürfungen und Prellmarken im Bereich des Schultereckgelenks.